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Abstract: As the HIV population ages, the prevalence of cognitive impairment (CI) is increasing, yet 
few services exist for the assessment and management of these individuals. Here we provide an 
initial description of a memory assessment service for people living with HIV and present data from 
a service evaluation undertaken in the clinic. We conducted an evaluation of the first 52 patients 
seen by the clinic. We present patient demographic data, assessment outcomes, diagnoses given and 
interventions delivered to those seen in the clinic. 41 patients (79%) of those seen in the clinic had 
objective CI: 16 (31%) met criteria for HIV-associated Neurocognitive Disorder (HAND), 2 (4%) 
were diagnosed with dementia, 14 (27%) showed CI associated with mental illness and/or 
drugs/alcohol, 7 (13%) had CI which was attributed to factors other than HIV and in 2 (4%) patients 
the cause remains unclear. 32 (62%) patients showed some abnormality on Magnetic Resonance 
Imaging (MRI) brain scans. Patients attending the clinic performed significantly worse than 
normative scores on all tests of global cognition and executive function. Interventions offered to 
patients included combination antiretroviral therapy modification, signposting to other services, 
case management, further health investigations and in-clinic advice. Our experience suggests that 
the need exists for specialist HIV memory services and that such a model of working can be 
successfully implemented into HIV patient care. Further work is needed on referral criteria and 
pathways. Diagnostic processes and treatment offered needs to consider and address the 
multifactorial aetiology of CI in HIV and this is essential for effective assessment and management. 
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1. Introduction 
In the UK over 100,000 people are chronically infected with HIV, with over 6000 new cases 
reported each year [1]. Cognitive impairment (CI) in patients living with HIV (PLWH) is commonly 
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reported and is likely to become an increasingly important issue as this population ages. HIV-
associated dementia, which occurred in up to 50% of PLWH prior to the introduction of potent 
combination antiretroviral therapy (cART), is now rare, however, mild to moderate CI is widely 
reported and results in lower quality of life, poorer adherence to medication, increased 
unemployment and reduced life expectancy [2–4]. Prevalence rates vary widely, depending on 
definitions of CI, with estimates reported as high as 52% [5]. Studies with tighter definitions estimate 
that between 14%–28% of PLWH over 50 years old have CI [6], which may or may not be associated 
with HIV. The term HIV-Associated Neurocognitive Disorder (HAND) has been coined to refer to a 
spectrum of impairments (Asymptomatic Neurocognitive Impairment (ANI); Mild Neurocognitive 
Disorder (MND); and HIV-associated Dementia (HAD)). The main method used to define HAND are 
the Frascati criteria [7]. These involve neuropsychological testing across multiple cognitive domains, 
HAND is diagnosed when two or more domains are more than one standard deviation below 
normative scores and for MND and HAD when daily functions are affected. Recent studies have 
suggested that the Frascati criteria have poor sensitivity and specificity, and do not take into account 
the complexity of pathogenic mechanisms likely to contribute to CI in PLWH [7–9]. This lack of clarity 
in definition and diagnosis is a significant issue which affects the management of PLWH with CI. 
Indeed, the pathogenic mechanisms causing CI are often multifactorial, including complex 
immunopathological processes controlled by HIV factors, the direct effects of cART, and host factors 
(e.g., co-infections, cardiovascular and cerebrovascular diseases, psychiatric illnesses, the effect of age 
and age-related illnesses on the brain and lifestyle factors, including social isolation [10]). 
Given the aetiological complexities PLWH with CI experience, where causation, diagnosis 
and/or management may all be unclear, patients might benefit from a multidisciplinary response. 
Serial consultations with HIV physicians, neurologists, dementia specialists, neuropsychologists and 
clinical psychologists may be time-consuming, uncoordinated and imperfectly synthesised. 
Additionally, in terms of management they may require psychological input and sign-posting to 
other specialist services for further investigation or management. While there are criteria to identify 
HAND, few recommendations exist on how best to manage and follow-up patients found to have CI 
and treated HIV. No guidance exists on how to address the clinical, social and psychological needs 
of HIV patients with progressive cognitive impairments and early dementia, regardless of CI 
pathology. In practice, the patient will often be referred to multiple services adding complexity, 
reducing efficiency and increasing social and economic burden. Moreover, in clinical experience we 
find joint clinics run outside of the HIV clinical setting have higher levels of non-attendance than 
equivocal clinics held within our normal HIV service setting. Importantly, patients complaining of 
CI and sign-posted to other services for assessment or investigation often struggle to remember 
where to go or who they are seeing and report feeling anxious about disclosing HIV-status, creating 
a further barrier to care [11]. 
In order to address these issues and generate a clear and efficient pathway for PLWH with CI 
and given the large numbers of people growing older with HIV in the Brighton area, the Orange 
Clinic was set up in 2016 as a collaboration between HIV services, memory assessment services and 
Brighton and Sussex Medical School. It aims to provide a single point of call for expert, 
multidisciplinary assessment, management and advice on care for PLWH with concerns about CI. 
Here we provide an initial description of the service and present data from the service evaluation 
undertaken of the clinic as a case study. We then use these experiences to make preliminary 
recommendations for the assessment and management of PLWH with cognitive complaints.  
2. Materials and Methods 
2.1. Clinical Setting 
The Orange Clinic team consists of (i) an HIV consultant physician, (ii) a consultant old age 
psychiatrist skilled in dementia assessment and management, (iii) a neuropsychologist with a 
psychology assistant, (iv) a clinical psychologist, (v) a HIV clinical nurse consultant and (vi) virtual 
support from neurology and neuroimaging services. The clinic operates for assessments for two 
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sessions on a monthly basis with an additional monthly follow-up session. In one day, the clinic aims 
to have completed multiple assessments and to triangulate the information from these with history 
and investigations to generate for each referral a full assessment and management plan. Referrals to 
the clinic may come from any healthcare professional involved in patient care and indications for 
referral are PLWH with cognitive complaints, or unexplained cognitive disorders where the referring 
team would like help with diagnosis and/or management. Prior to clinic attendance, a 
multidisciplinary virtual (without a patient present) case-based discussion of each patient is 
organised, this includes: a background review, evaluation of current knowledge/assessments and a 
review of the need to request further investigations (e.g., MRI or Lumbar Puncture (LP)) prior to 
assessment. Relatives or friends of the patients are encouraged to attend the clinic assessment, to 
provide a collateral history. The patient is interviewed jointly by the consultants in HIV, psychiatry 
and clinical psychology. The patient has a detailed neuropsychological assessment completed and all 
these data and any diagnosis are discussed by the multidisciplinary team as a whole and with the 
PLWH, following which a formulation and management plan is agreed, co-produced by all.  
2.2. Neuropsychological Assessments 
We have developed a test battery that is adapted to the clinical needs of the clinic. Using 
established assessments, proven sufficiently valid and reliable across a variety of populations, each 
patient attending the clinic is assessed in the broad domains of premorbid IQ and global cognition 
across multiple cognitive domains, including memory, attention, language processing, visuospatial 
processing and executive functioning (see Table 1 for neuropsychological tests performed). 
Table 1. Neuropsychological tests used in the Orange Clinic. 
Neuropsychological Test Test Description 
Montreal Cognitive Assessment (MoCA) [12] Completed prior to clinic attendance, this screening test is designed to 
detect Mild Cognitive Impairment (MCI) and Alzheimer’s disease across 
five domains. Scored out of 30, ≥26 is considered normal, ≤23 indicative 
of MCI and >17 of AD [12]. 
Test of premorbid functioning UK version 
(TOPF) [13] 
The TOPF is a word reading task designed to assess estimated premorbid 
functioning [13]. 
Reynolds Intellectual Screening Test (RIST) 
[14] 
The RIST provides a measure of general intelligence (14). An index score 
is calculated based on its two subtests which examine vocabulary 
knowledge and nonverbal reasoning. 
Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS) [15,16] 
The RBANS is a brief assessment battery from which five index scores 
can be derived from each of its subtests: memory, language, visuospatial 
processing and attention. It has demonstrated strong diagnostic accuracy 
for Alzheimer’s disease and MCI [17,18]. 
Trail Making Test [19] The Tombaugh (2004) version of the Trail Making Test was employed as 
a measure of executive functioning [19], with Part B noted to measure 
cognitive flexibility along with set shifting [20]. 
Delis Kaplan Executive Function Scale 
(DKEFS) colour word interference test [21] 
This subtest from the DKEFS [21] is a version of the classic ‘stroop’ 
colour-word interference task, which was employed as a test of executive 
functioning to measure inhibitory control. 
Neuropsychological Assessment Battery—
Screening Module (NAB-SM) mazes task [22] 
One subtest from the screening module of the NAB-SM [22] is included 
in this battery to provide a basic test of planning. 
2.3. Psychological Assessment 
Depression Anxiety and Stress Scale—21 item version (DASS21): The DASS21 is a short form 
version of the Depression Anxiety and Stress Scale [23]. Scores on each domain are categorised into 
normal (Depression, 0–9; Anxiety, 0–7; Stress, 0–14), mild (Depression, 10–13; Anxiety, 8–9; Stress, 
15–18), moderate (Depression, 14–20; Anxiety 10–14); Stress 19–25), severe (Depression, 21–27; 
Anxiety, 15–19; Stress, 26–33) and extremely severe (depression 28+; Anxiety, 20+; Stress 34+).  
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2.4. Quality of Life Assessments 
EuroQol five-dimension descriptive system (EQ-5D-5L): The EQ-5D-5L [24] is a brief self-
reported measure of generic health that consists of five dimensions. There is extensive literature 
supporting the validity and reliability of the measure across many conditions and populations 
[25,26]. In the clinic, to provide a brief sense of overall health perceptions, we recorded how patients 
rated their health out of 100, with 0 being the worst health imaginable.  
DEMQOL: DEMQOL [27] is a dementia-specific interviewer-administered health related quality 
of life questionnaire appropriate for use at all stages of dementia severity with self- (28 items) and 
proxy-report (32 items) versions. It has been used in memory service populations with all levels of 
CI, including those with Mild Cognitive Impairment and none [28]. 
2.5. Diagnosis 
Criteria for specific diagnoses within the clinic are based on interpretation of an individuals’ test 
scores, along with the clinical assessment of other relevant factors. These include: patients’ mood 
(both self-reported and on mental state examination); neuropsychological presentation, including the 
collateral history (i.e., a profile may suggest co-existing Alzheimer’s disease (AD)); past medical 
history and imaging results (e.g., If traumatic brain injury has occurred in the past, are the pattern of 
neuropsychological test results more consistent with damage caused to this area by the injury); effort; 
fatigue; test properties, including the relative psychometric properties of individual tests and the 
commonality of abnormally low scores within the general population; and limitations on test 
performance due to motor or sensory deficits and language barriers (e.g., English not being a patient’s 
first language). Thus, in the clinic, multiple variables, not just scaled test scores, are considered when 
assessing the presence and aetiology of impairment and diagnosis. 
3. Results 
From June 2016 to May 2018 the Orange Clinic assessed 52 patients. Demographic, HIV and 
health data of patients attending the clinic are presented in Table 2. 
Table 2. Demographic, HIV and health data of patients attending the clinic. 
Variable  Total 
Demographic Data  
Median age in years (range) ** 55 (36–84) 
Male (%) 41 (79)  
White (%) 43 (83)  
Black British/African (%) 
Asian 
MSM (%) 
Heterosexual (%) 
Other (%) 
7 (13) 
2 (4) 
38 (73) 
13 (25) 
1 (2)  
Referral source:  
HIV Physician (%) 33 (63) 
Memory Assessment Service (%) 4 (8) 
Neurology Service (%) 3 (6) 
Community HIV specialists (%) 3 (6) 
Mental Health Services (%) 1 (2) 
Other (%) 8 (15) 
HIV Clinical Data  
Time since HIV diagnosis (years) ** 17 (1–34) 
Duration of cART (years) ** 13 (1–22) 
Nadir CD4 count (cells/μL) * 312.27 (207.48) 
Current CD4 count (cells/μL) * 689.37 (279.45) 
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Current CD8 count (cells/μL) * 920.98 (410.06) 
CD4:CD8 ratio 0.87 (.47) 
VL >40 (%) 4 (8)  
On cART (%) 51 (98) 
On PI based regimen (%) 12 (24) 
On PI based and NRTIs regimen (%) 13 (25) 
On NRTI and NNRTI regimen (%) 18 (35) 
On another combination of regiment (%) 9 (17) 
Health Data  
Smoking (% smokers) 12 (23) 
Alcohol intake (units/week) ** 2 (0–90) 
Recreational drugs (% use) 
Cannabis (%) 
Methedrone 
GHB 
Other 
16 (31) 
10 (16) 
4 (25) 
3 (19) 
5 (31) 
CVD Risk (RISK2) * 10.34 (9.45) 
Mean number (range) non-HIV medications 
Antidepressants (%) 
4.6 (0–20) 
24 (46) 
Statins (%) 14 (27) 
Antiplatelets (%) 8 (15) 
Analgesia (%) 12 (23) 
PPI (%) 12 (23) 
Other (%) 33 (63) 
Polypharmacy (≥3 non-HIV medications, %) 26 (50) 
MSM, men who have sex with men; cART, combination antiretroviral therapy; PI, Protease Inhibitor; 
NRTI, Nucleoside reverse transcriptase inhibitor; NNRTI, Non-nucleoside transcriptase inhibitor; 
CVD, cardiovascular disease; PPI, proton pump inhibitor. All values are expressed as n, unless 
otherwise stated. * mean (standard deviation). ** median (range). 
Of the 52 patients seen, 42 had HAND based on Frascati criteria. Using our diagnostic criteria, 
we found 11 (21%) patients to have no objective CI, 16 (31%) were diagnosed with HAND, 2 (4%) 
were diagnosed with dementia (one AD, 1 unspecified). In 14 (27%) the CI was assessed as being 
secondary to mental health difficulties (depression, anxiety, OCD, poor sleep) and/or drug/alcohol 
abuse, 7 (14%) had CI which was attributable to factors other than HIV (2 prior Traumatic Brain Injury 
(TBI), 4 cerebrovascular diseases and 1 cortical dysplasia), and in 2 (4%) cases the CI cause remains 
unclear (both are recent cases and we are awaiting LP/MRI or other investigations).  
All but one patient had a new (n = 28) or recent MRI (n = 23) and 32 (62%) had some type of MRI 
brain abnormality. White matter (WM) hyperintensities were the most common finding (n = 22), of 
these 11 were considered vascular and indicative of cerebrovascular issues (i.e., ischaemia or small 
vessel disease). 8 scans showed evidence of cortical atrophy and 6 of subcortical atrophy. 4 patients 
demonstrated abnormalities consistent with HIV-associated CI (e.g., damage from previous HIV-
associated encephalitis or leukoencephalopathy). 5 patients’ scans had ‘other’ abnormalities, 
including meningioma, pontine lesions, left insular lesions, hyperintensities of the pons and siderosis.  
Lumbar Punctures (LPs) were requested for 26 patients attending the clinic. Patients did not 
receive a LP when it was considered unnecessary (e.g., likely mental health causation for CI) or when 
patients refused it. Within our cohort there was no recorded cases of CSF escape.  
The majority of patients were assessed using the Montreal Cognitive Assessment (MoCA) [12] 
prior to clinic attendance and the mean score was 23.6 (2.6). All other neuropsychological test scores 
were converted into Standard Scores (SS) to allow comparison of data (Mean = 100, SD = 15). Test of 
premorbid functioning (TOPF) clinic mean was 99.2 (11.8) and Reynolds Intellectual Screening Test 
(RIST) clinic mean was 99.1 [15], indicating that the general intelligence of our sample was similar to 
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the population mean. Mean performance on Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS) total scale was 80 (17.3) and on each RBANS domain: immediate 
memory, 82.2 (20.8); visuospatial, 94.5 (18.9); language, 86.5 (15.5); attention, 79.9 (16.9); delayed 
memory, 79.2 (21.5). Figure 1 shows the mean RBANS scores seen in those attending the clinic against 
average scores reported in the literature from patients with Alzheimer’s dementia and mild cognitive 
impairment [29,30]. Interestingly, women (n =11) attending the clinic were outperformed by males 
on all measures, with statistically significant differences on measures of premorbid functioning 
(males in our cohort had higher premorbid IQ) (p < 0.01) as well as the mazes task (p = 0.02), 
visuospatial (p < 0.01), language (p = 0.001) and attention (p = 0.02) indices of the RBANS and the 
RBANS overall score (p = 0.01). Differences seen are likely due to differences in premorbid IQ, and 
that women attending the clinic tended to be from different cultural (i.e., where English is not the 
first language) and socio-economic backgrounds to the men.  
 
Figure 1. Average RBANS scores of clinic patients against average scores reported in the literature 
from patients with Alzheimer’s dementia and mild cognitive impairment [29,30]. 
One-sample t-tests suggest that scores on Total RBANS score were significantly worse in patients 
attending our clinic (80 ± 17.32) than normative scores (100 ± 15), t (51) = −8.31, p < 0.001. Indeed, our 
clinical cohort performed on average significantly worse than normative scores across all RBANS 
subdomains; Immediate memory (82.19 ± 20.75), t (51) = −6.19, p < 0.001; Visuospatial (94.54 ± 18.85), 
t (51) = −2.09, p = 0.04; Language (86.46 ± 15.46), t (51) = −6.31, p < 0.001; Attention (79.87 ± 16.9), t (51) 
= −8.59, p < 0.001; Delayed memory (79.21 ± 21.55), t (51) = −6.96, p < 0.001). Patients also completed a 
range of executive functioning tests. One-sample t-tests again revealed those attending the clinic 
performed significantly worse than normative scores (100 ± 15) in all executive functioning tests: NAB 
screening module mazes (89.63 ± 18.66), t (50) = −3.97, p < 0.001; DKEFS colour word interference test 
(83.79 ± 18.72), t (41) = −5.61, p < 0.001; Trails Test A (81.40 ± 20.14), t (49) = −6.53, p < 0.001; Trails Test 
B (74.37 ± 23.07), t (42) = −7.29, p < 0.001. 
3.1. Mental Health and Quality of Life Assessments 
The mean score on total DASS21 across the patients attending the clinic was 27 (SD = 13.4), the 
mean depression score was 8 (52), the mean anxiety score was 8 (4.9) and the mean stress score 11.0 
(5.3). Across the clinic the mean ED-5Q-5L score was 65 (23.9) and mean DEMQOL total score was 70 
(17.1). We found no correlation between EQ-5D-5L score and DEMQOL total score and no correlation 
between any of the HIV data variables and either DEMQOL total score or ED-5Q-5L score. The scores 
on DEMQOL are indicative of a lower quality of life than in the population of those attending 
memory assessment services where the mean DEMQOL score at assessment of 197 attenders was 89.6 
(14.1); t (247) = 8.47, p < 0.0001 [31].  
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3.2. Management 
Patients attending the clinic received a variety of interventions, referrals and advice. These are 
summarised in Table 3. 
Table 3. N and type of intervention administered by the clinic. 
Management Type N 
MRI 20 
LP 22 
Request Blood Tests 6 
CT/ PET Scan 2 
Neurology advice 5 
Request genotyping of CSF virus 2 
Switch/review/intensify cART 14 
Request other health investigation 9 
Review/modify co-medication 11 
Refer to generic Mental Health Services 16 
Refer to HIV Mental Health Specialist Services 8 
Refer to community HIV Specialist nursing team 12 
Refer to Other Health Services 5 
Signpost to a non-HIV community service 6 
Control CVD risk factors 11 
In clinic advice: Cognitive strategies/remediation 10 
In clinic advice: Lifestyle 14 
In clinic advice: Mental health management 7 
In clinic advice: cART adherence 5 
Total 185 
Of the 52 patients who attended the clinic, 23 are now discharged. Of those discharged, 9 had no 
objective CI, 8 had CI due to mental health issues which were best served by other services, 1 patient 
had CI due to prior HIV encephalitis, 1 had CI due to a previous traumatic brain injury, and 3 had 
mild HAND. 10 of these patients were discharged following initial appointment. These patients were 
given in-clinic advice (n = 9), referred to mental health services (n = 3), referred to community drug 
support services (n = 1) and provided with a recommendation for strict control of cardiovascular risk 
factors (n = 1). The other 12 were discharged following satisfactory feedback from further 
investigations or once a management plan had been fully implemented and the one patient with 
Alzheimer’s disease died. 
29 patients are still open to the clinic. Of these 15 are due to have repeat cognitive testing to 
assess progression and/or impact of management plan and a further 8 are due to be followed-up 
following implementation of management plans (e.g., psychological therapy, in-clinic advice on 
lifestyle/mental health management e.g., sleep hygiene, medication changes, stricter control of CVD 
risk factors). 2 patients will be reviewed again following MRI/LP/other health assessment feedback 
before a management plan is devised. Finally, 4 patients remain open to the clinic but are not due to 
be seen unless needed, these patients are all either responding well to their current plan or have been 
referred to another health service.  
4. Discussion 
Historically, PLWH have looked to their HIV clinic to manage their medical, and in some cases, 
social and psychological needs. HIV services have always been active in adapting and innovating 
care models to provide for the changing needs of their patients. The Orange Clinic represents such a 
model—a novel, needs-driven, efficient and coordinated service for the ageing population of PLWH 
who experience neurocognitive issues, which is in keeping with NHS England’s 5-year forward view.  
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Patients attending the clinic varied widely in age (36–84 years), and in time since virus 
acquisition (1–34 years). Our cohort is distinctive in that 73% of patients were MSM, whereas current 
UK statistics show 55% of PLWH identify as heterosexual [32]. All but one patient was on cART, 
which is in line with the national average of 96%, and all but four patients had a VL <40 copies/mL. 
Of these, three were diagnosed with HAND and one with dementia, all had their cART switched (or 
in one case re-started).  
Based on Frascati criteria, 81% of patients attending the clinic would be diagnosed with HAND. 
Using our diagnostic processes, we found 79% had an objective CI, however of these, 61% had a 
reason for this that was not HIV-related and only 39% had ‘true’ HAND. This highlights that the 
Frascati criteria when applied to data in isolation from other factors (e.g., patient mood, nature of 
neuropsychological presentation, past medical history, imaging data, effort, fatigue, relative 
psychometric properties of individual tests) do not correlate well with interpretation of test scores by 
experienced neuropsychologists, largely because this model does not account for the extensive range 
of possible confounding variables that are present in clinical samples. Whilst these may be of use in 
research settings, in clinical practice the use of the Frascati model may miss much that is of clinical 
importance and lacks utility when considering and producing management plans.  
This high prevalence of CI detected is in line with the purpose of the clinic, and the heterogeneity 
of causation of CI in HIV is well illustrated. None had HIV dementia, our main test of global 
functioning (RBANS) supports research indicating the pattern of CI from pre and post cART eras has 
changed. AIDS-dementia complex, seen frequently in the pre-cART era, was characterized by 
progressive subcortical dementia with prominent degeneration of cognitive and motor functions. 
Our clinic patients diagnosed with HAND (based on our diagnostic criteria) showed impairments in 
tests of immediate and delayed memory, with mild impairments in attention, visuospatial skills and 
language—demonstrating a more subtle subcortical involvement and cortical involvement possibly 
influenced by age [33].  
It is significant that 27% of those who attended the clinic had a mental health condition which 
was likely to be responsible for their subjective and objective CI. A number of other patients attending 
the clinic were also experiencing poor mental health which was not thought to be causing their CI. It 
is also striking that 44% of patients were taking antidepressant medication. Current management of 
depression in HIV relies primarily on antidepressant medication [34] with open-label trials of 
different antidepressants, across HIV illness stage, showing response rates of 70%–90% (equivalent 
to non-HIV infected populations) and good levels of tolerance [35–37]. A recent systematic review 
examining the efficacy of different interventions for PLWH experiencing depression, found that 
psychotropic and HIV-specific psychological interventions incorporating a cognitive behavioural 
component were most effective [38]. In our clinic it has been vital to be able to address the mental 
health issues of patients. This has involved either referrals to HIV specialist mental health services (if 
mental health issues are related to HIV issues such as diagnosis) (n = 8) or to general mental health 
services (n = 16).  
Where social isolation or drug and alcohol issues are a concern, patients have been directed to 
different community services (n = 6). We have also given in-clinic advice on mental health 
management (n = 7) and initiated treatment ourselves when urgent. Our data show how important it 
is to have the skills available to assess mental health and clear pathways for those attending HIV 
services who have problems with CI. The relationship between HIV, mental illness, and CI is 
complex. The psychological and social impact of an HIV diagnosis (stigma, discrimination and 
isolation) can contribute to symptoms of depression and anxiety, and therefore to subjective and 
objective CI. In addition, HIV replication in the Central nervous system (CNS) causes depression via 
the modification of brain structures [39], somatostatin dysregulation [40] and increased inflammatory 
cytokines [41], as well as lowering cognitive reserve and impairing cognitive function directly and 
via co-infection. Added into this are lifestyle factors such as drug and alcohol use which may be 
exacerbated by mental health issues and will have a negative impact on cognitive function.  
The finding that our clinic population has a much lower quality of life than that of people 
attending memory services is of interest. This suggests that these concerns about CI in the context of 
Brain Sci. 2019, 9, 37 9 of 12 
HIV, and with high comorbidity with mental disorders, act to decrease the quality of life of those 
with HIV and CI. It is striking that the condition-specific measure DEMQOL picked this up while the 
generic EQ-5D-5L did not. We used DEMQOL, despite it having been designed for individuals with 
dementia and MCI, as it captures many of the experiences which likely dictate quality of life for those 
with HIV and CI such as feeling understood when trying to express oneself and having enough social 
company. In the clinic while the results need to be interpreted with caution, it does provide us with 
useful extra information and informs interventions offered.  
Early (and efficient) detection of milder forms of HAND (i.e., ANI) is a priority, with the British 
HIV Association (BHIVA) recommending all PLWH should be screened annually for CI. However, 
there are barriers to this in terms of the lack of quick, efficient and valid screening tools (particularly 
with the ability to detect milder forms of HAND) and to the lack of evidenced-based treatment 
guidelines about what to do once it is found. The clinical relevance of seeking to ‘diagnose’ 
‘asymptomatic’ CI has been called into question as wasteful of resources and needlessly worrying to 
patients. Recent findings have shown that ANI is predictive of further cognitive decline [42] but the 
main moderators of these changes are common to all, including older age, cardiovascular risk factors 
(diabetes, hypertension, smoking), presence of depression and other health comorbidities [42–44]. 
Medication treatment strategies for CI have generally proved disappointing, within the clinic we 
modified cART regimens only due to patient complaint of side effects (and would have modified if 
presence of CSF HIV RNA was detected); besides this little recommendation or indeed clarity of 
evidence exists. Improvements in neurocognition using medications with better CNS penetration or 
maraviroc is widely debated [45–47] and while evidence points to neurotoxicity associated with some 
regimens (i.e., Efavirenz), clarity around the most efficacious cART regimen to use with patients 
living with HAND is unclear. In HIV-negative populations, potential benefits of early recognition of 
CI include protection from unsafe situations, increased quality of life through information sharing, 
and improved life planning [47]. These are also likely to be relevant to those with HIV.  
Interventions addressing cardiovascular risk factors and mental wellbeing appear to be of value 
[42,44]. At the clinic we offer patients informal advice on lifestyle (e.g., diet, exercise, sleep hygiene, 
drugs/alcohol intake), mental health management, adherence to cART and cognitive strategies, along 
with recommendations to their GP on the control of CVD risk factors. We plan quantitative 
evaluation of the effectiveness/utility of the clinic, along with qualitative experiential data from 
current patients. Furthermore, we are planning to evaluate the clinical use of inflammatory 
biomarkers and markers associated with HAND to aid diagnostic uncertainty in PLWH. A biomarker 
that has shown promise is the neurofilament light chain protein (NFL) [48] which could be used in 
routine clinical practice to define those patients more likely to have HAND. APOE 4 carriage has 
also been suggested as a potential predictive marker for HAND. Evidence regarding the role of APOE 
in PLWH with HAND is conflicting. A study based on the Hawaii Aging with HIV cohort [49] (n = 
182) associated APOE 4 carriage with HAND, but only with older participants. A large ethnically 
diverse cohort (n = 2399) found an association with APOE 4 and acceleration of HIV disease, but not 
HAD (the authors only examined HAD and did not assess complete HAND spectrum) [50]. More 
recently in the CHARTER study (N = 466) participants received a comprehensive HAND assessment 
and no association was found between APOE 4 carriage and HAND [51]. Interestingly, the authors 
note that differences between studies may be due to the age of the sample; only 4% of their sample 
was over 60 years of age, compared to 25% in the Hawaii cohort and therefore results may not 
preclude the emergence of an association between HAND and APOE 4 status as this population 
ages.  
5. Conclusions 
In the UK, 48% of those accessing HIV services are now aged 45 and over, with large increases 
seen in those of an older age in the past decade. Recent modelling work predicts that by 2030 73% of 
PLWH will be over 50 years of age [52]. Multidisciplinary working is vital to the successful 
management of such patients where complex multimorbidity is likely to be the norm. This service 
evaluation provides tentative evidence that the need exists, that the model of care we have developed 
Brain Sci. 2019, 9, 37 10 of 12 
is feasible and that there may be value in establishing similar models of working in HIV care for those 
with impairment in cognitive function.  
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